Cara Therapeutics (US)

Cara is a Connecticut-based company developing novel itch, pain and inflammation therapeutics. Its lead drug, CR845, is a highly selective, peripherally restricted kappa opioid receptor agonist currently in Phase 3 clinical development for uremic pruritus and postoperative pain. For more information, visit www.caratherapeutics.com

Category

Case Studies